The natural course of non-alcoholic fatty liver disease

被引:9
作者
Seval, Guldane Cengiz [1 ]
Kabacam, Gokhan [2 ]
Yakut, Mustafa [2 ]
Seven, Gulseren [2 ]
Savas, Berna [3 ]
Elhan, Atilla [4 ]
Cinar, Kubilay [1 ]
Idilman, Ramazan [2 ]
机构
[1] Ankara Univ, Dept Internal Med, Sch Med, Ankara, Turkey
[2] Ankara Univ, Dept Gastroenterol, Sch Med, TR-06100 Ankara, Turkey
[3] Ankara Univ, Dept Pathol, Sch Med, Ankara, Turkey
[4] Ankara Univ, Dept Biostat, Sch Med, Ankara, Turkey
来源
HEPATOLOGY FORUM | 2020年 / 1卷 / 01期
关键词
Cirrhosis; non-alcoholic fatty liver disease; steatohepatitis;
D O I
10.14744/hf.2020.0008
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aim: The present study aims to describe the characteristics and long-term clinical outcomes of patients with non-alcoholic fatty liver disease (NAFLD). Material and Methods: A total of 1308 individuals with NAFLD were seen in the Liver Diseases Outpatient Clinic. Diagnosis of NAFLD in each case was based on biochemical, radiological and histological criteria, when available. After diagnosis, all NAFLD patients were administered a conventional diet and exercise program. The median follow-up period was 55.3 months. Results: At the time of the diagnosis, the mean age was 50.8 +/- 11.3 years, and female gender was slightly predominant (51.4%). The median body mass index was 29.2 +/- 4.7 kg/m(2) : 39% were obese. Seventeen percent of the patients had diabetes mellitus, 53% insulin resistance, 60% hyperlipidemia, and 32% hypertension. Median serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase levels were 31 U/L (range: 10-248 U/L), 45 U/L (range: 10-285 U/L) and 41 (range: 8-1200 U/L), respectively. Liver biopsy was performed in 293 individuals. The median NAFLD activity score was 5.0, median hepatic steatosis 2, ballooning 1, lobular inflammation 1, portal inflammation 0, and fibrosis 0. Of note, 41.3% of the samples (121/293) revealed the presence of fibrosis and 31% of the samples (37/121) showed significant fibrosis. With multivariate analysis, diabetes and obesity were associated with the presence of significant fibrosis. Among them, 765 patients (M/F: 353/412, mean age: 51.0 +/- 10.9) had at least six months of follow-up. In this group, from baseline to the end of the follow-up period, a significant improvement in the serum AST and ALT levels was observed. Conclusion: NAFLD is a potentially progressive disease. Diabetes and obesity were associated with the presence of advanced fibrosis.
引用
收藏
页码:20 / 24
页数:5
相关论文
共 50 条
  • [31] Non-alcoholic fatty liver disease
    Powell, Elizabeth E.
    Wong, Vincent Wai-Sun
    Rinella, Mary
    LANCET, 2021, 397 (10290) : 2212 - 2224
  • [32] Non-Alcoholic Fatty Liver Disease
    Engin, Atilla
    OBESITY AND LIPOTOXICITY, 2017, 960 : 443 - 467
  • [33] Non-alcoholic fatty liver disease
    Sattar, Naveed
    Forrest, Ewan
    Preiss, David
    BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
  • [34] Features of the course of gallstone disease in patients with non-alcoholic fatty liver disease
    Cherkashchenko, N. A.
    Livzan, M. A.
    Krolevets, T. S.
    TERAPEVTICHESKII ARKHIV, 2020, 92 (02) : 48 - 54
  • [35] Natural flavonoids: Potential therapeutic strategies for non-alcoholic fatty liver disease
    Tan, Panli
    Jin, Li
    Qin, Xiang
    He, Beihui
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [36] Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Albanian overweight children
    Kodhelaj, K.
    Resuli, B.
    Petrela, E.
    Malaj, V.
    Jaze, H.
    MINERVA PEDIATRICA, 2014, 66 (01) : 23 - 30
  • [37] Parental non-alcoholic fatty liver disease increases risk of non-alcoholic fatty liver disease in offspring
    Long, Michelle T.
    Gurary, Ellen B.
    Massaro, Joseph M.
    Ma, Jiantao
    Hoffmann, Udo
    Chung, Raymond T.
    Benjamin, Emelia J.
    Loomba, Rohit
    LIVER INTERNATIONAL, 2019, 39 (04) : 740 - 747
  • [38] Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design
    Allen, Alina M.
    Therneau, Terry M.
    Ahmed, Omar T.
    Gidener, Tolga
    Mara, Kristin C.
    Larson, Joseph J.
    Canning, Rachel E.
    Benson, Joanne T.
    Kamath, Patrick S.
    JOURNAL OF HEPATOLOGY, 2022, 77 (05) : 1237 - 1245
  • [39] Effect of resveratrol on non-alcoholic fatty liver disease
    Theodotou, Marios
    Fokianos, Konstantinos
    Moniatis, Demetris
    Kadlenic, Rudolf
    Chrysikou, Asimina
    Aristotelous, Andrea
    Mouzouridou, Alexia
    Diakides, John
    Stavrou, Eliza
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 18 (01) : 559 - 565
  • [40] Current treatment of non-alcoholic fatty liver disease
    Ahmed, Mohamed H.
    Byrne, Christopher D.
    DIABETES OBESITY & METABOLISM, 2009, 11 (03) : 188 - 195